Janux Therapeutics (NASDAQ:JANX) Stock Rating Lowered by Clear Str

Janux Therapeutics (NASDAQ:JANX) was downgraded by equities researchers at Clear Str from a “strong-buy” rating to a “hold” rating in a note issued to investors on Tuesday,Zacks.com reports.

JANX has been the subject of a number of other research reports. Bank of America lowered their price objective on Janux Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, December 2nd. Cantor Fitzgerald dropped their price target on shares of Janux Therapeutics from $200.00 to $150.00 and set an “overweight” rating for the company in a research note on Tuesday, December 2nd. Barclays cut their price target on shares of Janux Therapeutics from $48.00 to $29.00 and set an “overweight” rating on the stock in a report on Wednesday, December 17th. Piper Sandler reduced their price objective on shares of Janux Therapeutics from $42.00 to $30.00 and set an “overweight” rating on the stock in a research note on Friday, January 16th. Finally, Wedbush reissued an “outperform” rating and issued a $45.00 target price (down previously from $76.00) on shares of Janux Therapeutics in a research report on Tuesday, December 2nd. Eleven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $60.08.

Janux Therapeutics Price Performance

Janux Therapeutics stock opened at $13.27 on Tuesday. Janux Therapeutics has a 12-month low of $12.80 and a 12-month high of $47.58. The company has a market capitalization of $798.19 million, a price-to-earnings ratio of -7.90 and a beta of 2.88. The firm’s fifty day moving average price is $18.80 and its 200 day moving average price is $22.87.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.60) by $0.21. The firm had revenue of $10.00 million during the quarter, compared to analysts’ expectations of $3.07 million. Analysts forecast that Janux Therapeutics will post -1.38 earnings per share for the current fiscal year.

Insider Activity at Janux Therapeutics

In other Janux Therapeutics news, insider Andrew Hollman Meyer sold 1,879 shares of the stock in a transaction on Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $25,798.67. Following the sale, the insider directly owned 83,095 shares of the company’s stock, valued at approximately $1,140,894.35. This represents a 2.21% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas Diraimondo sold 2,505 shares of Janux Therapeutics stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $13.73, for a total transaction of $34,393.65. Following the completion of the transaction, the insider directly owned 124,425 shares of the company’s stock, valued at $1,708,355.25. This trade represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 42,364 shares of company stock valued at $972,185 in the last ninety days. 8.10% of the stock is owned by insiders.

Hedge Funds Weigh In On Janux Therapeutics

Several institutional investors have recently modified their holdings of JANX. Squarepoint Ops LLC boosted its stake in Janux Therapeutics by 230.0% during the 2nd quarter. Squarepoint Ops LLC now owns 189,569 shares of the company’s stock valued at $4,379,000 after purchasing an additional 132,121 shares during the period. Quinn Opportunity Partners LLC raised its holdings in shares of Janux Therapeutics by 15.4% during the second quarter. Quinn Opportunity Partners LLC now owns 59,893 shares of the company’s stock valued at $1,384,000 after buying an additional 8,000 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Janux Therapeutics by 15.5% during the second quarter. Geode Capital Management LLC now owns 902,312 shares of the company’s stock worth $20,845,000 after buying an additional 121,403 shares during the period. AlphaQuest LLC boosted its position in shares of Janux Therapeutics by 3,658.9% during the second quarter. AlphaQuest LLC now owns 9,698 shares of the company’s stock worth $224,000 after buying an additional 9,440 shares during the period. Finally, Capital Fund Management S.A. bought a new position in Janux Therapeutics in the 2nd quarter worth approximately $757,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Company Profile

Janux Therapeutics is a clinical-stage biotechnology company focused on developing next-generation intratumoral immuno-oncology therapies that harness the body’s innate and adaptive immune systems. The company designs and synthesizes proprietary Toll-like receptor (TLR) agonists to reprogram the tumor microenvironment. Janux is publicly traded on the Nasdaq under the symbol JANX.

Its lead programs include JTX-8064, a fully synthetic TLR4 agonist engineered for optimal stability and potency, and JTX-4014, a TLR1/2 agonist formulated for direct intratumoral administration.